newsfilter
← Latest News
GlobeNewswire·

Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts

- Multi-asset pipeline with significant targeted data readouts and milestones -- Two lead ophthalmic gene therapy programs in clinical trials with new data anticipated in 2026 -- Supplemental New Drug Application (sNDA)